drugset / Trial / NCT03808701
Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced squamous non-small cell lung cancer treated after failure of Two chemotherapy regimens (including Platinum-based drugs).
Timeline
- Start
- 2019-03
- Primary completion
- 2019-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCT200 | Monoclonal antibody | 12 mg/kg | — |
| Subject | SCT200 | Monoclonal antibody | 15 mg/kg | — |